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Abstract
Whilst the benefit of direct-acting antiviral agents (DAAs) in achieving sustained vi-
rological response (SVR) is now well-accepted, their impact on liver function, particu-
larly in relation to achievement of SVR, has not been well documented. We studied 
2394 patients with chronic HCV infection, 1276 receiving DAAs and 1118 interferon-
based therapy. Liver function was assessed by the albumin-bilirubin (ALBI) score or 
grade. Overall survival according to SVR status and baseline ALBI grade was exam-
ined. We also studied time to first decompensation according to ALBI grade, as well 
as longitudinal changes in ALBI score over time according to SVR. Among the pa-
tients receiving DAAs, 89% achieved SVR (Japan = 99%, UK = 78%). Amongst the 
decompensated patients in the UK cohort, three distinct risk groups according to 
ALBI grade at baseline were observed. The UK patients receiving DAAs, who had 
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1  |  INTRODUC TION
The clinical benefits of achieving a sustained virological response (SVR) 
to antiviral therapy in patients with chronic hepatitis C virus (HCV) in-
fection have been extensively documented. These include a decrease in 
liver-related complications (such as hepatocellular carcinoma [HCC] and 
hepatic decompensation), non-liver-related complications (such as de-
velopment of insulin resistance and lymphoma), together with improve-
ments in quality of life for patients and economic benefit for healthcare 
providers.1-5 Improvement in fibrosis and even reversal thereof has also 
been observed6 and, it has been assumed, there is also improvement 
in liver function. Nonetheless, since DAAs have only recently been in-
troduced, there is very short follow-up, leading a recent Cochrane re-
view to conclude that ‘there are no long-term trials that have assessed 
whether or not DAA treatment improves morbidity or mortality’7 al-
though this opinion has been robustly challenged.1 Furthermore, it has 
even been suggested that the ‘uncertain clinical benefit’, along with the 
risks and costs of DAA therapy, should be discussed with patients to 
allow a shared decision on treatment to be made.7
We have recently shown that several of the factors involved 
in the Childs-Pugh score (CPS), the conventional measure of liver 
function, are ‘redundant’. Thus, the CPS can be refined in a simple 
algorithm to involve only serum albumin and bilirubin (the albu-
min-bilirubin score [ALBI]).8 The model was originally developed 
for patients with HCC and has been extensively validated.9 More 
recently, the model has been validated in patients with chronic liver 
disease without HCC.10 The ALBI score has the advantage that, as 
well as avoiding the necessity of using highly subjective variables 
(ascites and encephalopathy) as required for the Child-Pugh score, it 
has sufficient granularity to permit sensitive quantification of serial 
changes in liver function over time.
Our primary aim here is to report changes in liver function in pa-
tients with decompensated disease consequent upon treatment with 
direct-acting antiviral agents (DAAs), but for comparison, we also in-
clude a large cohort of patients with compensated disease also treated 
with DAAs. A cohort of patients receiving interferon-based therapies 
is also included to give an indication of how liver function can change 
over the long term in response to effective antiviral treatment.
2  |  PATIENTS AND METHODS
We studied 2394 patients with chronic HCV infection, 1276 receiving 
DAAs and 1118 receiving interferon-based therapy. Those receiving 
DAAs came from the UK (n = 602, median follow-up = 23.7 months 
[95% CI 23.5, 24.0], all with decompensated cirrhosis) and Japan 
(n = 674, median follow-up = 20.7 months [95% CI 20.5, 21.0], all with 
compensated disease). The Japanese cohort receiving interferon-
based therapies (n = 1118, median follow-up = 11.0 years [95% CI 
10.3, 11.8]) had, mainly, compensated disease. Other virology data 
recorded included the HCV genotype, viral load and whether the 
patient achieved sustained virological response (SVR). Demographic 
features and the range of clinical parameters for the entire patient 
population recorded are listed in Table 1. The time at which antiviral 
treatment was initiated is henceforth referred to as ‘baseline’.
Patients were classified as having achieved SVR, relapse after ini-
tial response (REL) or no-response (NR) according to internationally 
agreed criteria.11 Because there were only very minor differences 
between those with REL and NR with regard to any of the recorded 
parameters, REL and NR were combined and analysed as a ‘non-SVR’ 
cohort. A small group of Japanese patients who underwent a sec-
ond course of DAA treatment (n = 17) were similarly classified; those 
who had response unclassified at the time of analysis were excluded.
2.1  |  The UK DAA cohort
This observational cohort comprised 602 patients prospectively 
collected and treated for liver disease within the NHS England 
Expanded Access Programme (EAP), data for which are held by 
predominantly decompensated disease, showed clear evidence of improvement of 
liver function detectable within 2 years of the start of treatment, especially in those 
achieving SVR. These early changes in liver function were very similar to those ob-
served in the first 2-3 years after interferon-based therapy. DAAs improve liver func-
tion especially in those with decompensated disease who achieve SVR. Experience 
with interferon-based therapy suggests that failure to achieve SVR is associated with 
long-term decline in liver function and, in contrast, patients who do achieve SVR can 
expect long-term disease improvement and subsequent stabilization of liver function. 
Our initial analysis suggests that those receiving DAAs are likely, in the long term, to 
follow a similar course.
K E Y W O R D S
ALBI score, direct-acting antivirals, hepatitis C virus, interferon therapy, liver function, 
sustained virological response
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the UK Biobank, HCV Research UK. Patients eligible for treatment 
within the EAP were those at significant risk of death or irreversible 
damage from HCV infection within 12 months, regardless of geno-
type. Patients were treated with 12 weeks of Sofosbuvir along with 
either Daclatasvir or Ledipasvir (at clinician discretion) and ribavirin 
(at clinician discretion). All patients included within this study con-
sented to contribute their data to the database.
All patients had decompensated chronic liver disease, with 
ascites, a history of variceal bleeding or encephalopathy or a 
Child-Pugh score greater than or equal to 7. Patients who had un-
dergone liver transplantation before or after antiviral therapy were 
excluded since this would likely have a dramatic effect on liver 
function, making these patients less representative of those with 
severe liver disease. Additional patients were treated within the 
TA B L E  1  Demographic and clinical features of the three cohorts
Variable
DAA-treated HCV patients IFN-treated HCV patients
Japan (N = 674) UK (N = 602) Japan (N = 1118)
Non-SVR (n = 9, 
1.3%)
SVR (n = 665, 
98.7%)
Non-SVR (n = 135, 
22.4%)
SVR (n = 467, 
77.6%)
Non-SVR (n = 459, 
41.1%)
SVR (n = 659, 
58.9%)












Male, n (%) 1 (11.1) 290 (43.6) 103 (76.3) 335 (71.7) 254 (55.3) 373 (56.6)
HCV genotype, n (%)
1 7 (77.8) 479 (72.0) 33 (24.4) 258 (55.3) 330 (71.9) 296 (45.0)
2 2 (22.2) 186 (28.0) 0 0 129 (28.1) 353 (53.7)
3 0 0 96 (71.1) 156 (33.4) 0 2 (0.3)
Other (1/2) 0 0 6 (4.4) 53 (11.4) 0 7 (1.1)




















































ALBI grade, n (%)
1 8 (88.9) 559 (84.1) 4 (3.0) 48 (10.3) 326 (71.0) 553 (83.9)
2 1 (11.1) 103 (15.5) 84 (62.2) 296 (63.4) 132 (28.8) 106 (16.1)
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Note: Highlighted figures represent the main differences between the cohorts.
Abbreviations: ALBI, albumin-bilirubin score; DAAs, direct-acting antiviral agents; HCV, hepatitis C virus; SVR, sustained virological response.
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EAP for extra-hepatic manifestations of HCV, but these patients 
were also excluded from the present study, which focuses on liver 
function. The present study comprises a cohort of patients treated 
between May 2014 and June 2015 giving a potential follow-up of 
15 to 28 months.12,13
2.2  |  The Japanese DAA cohort
Japanese patient data were prospectively collected between 
September 2014 and August 2016. A total of 674 patients with 
chronic HCV infection underwent anti-HCV therapy with IFN-free 
DAA regimens. No patients had decompensated cirrhosis since the 
use of DAAs is not permitted for patients with decompensated cir-
rhosis in Japan. Based on HCV genotype, patients received IFN-free 
DAA regimens that were approved by the Japanese National Medical 
Insurance system. Patients with HCV genotype 1 underwent a 24-
week regimen with Daclatasvir (DCV) and Asunaprevir (ASV) [1], a 
12-week regimen with Ledipasvir (LDV) and Sofosbuvir (SOF) [2], or 
a 12-week regimen with Ombitasvir (OMV), Paritaprevir (PRV) and 
Ritonavir (r) [3]. Patients with genotype 2 underwent a 12-week regi-
men with SOF and Ribavirin (RBV) [4].
2.3  |  The Japanese interferon-
based therapy cohort
We identified 1118 patients with chronic HCV infection treated with 
interferon-based therapy between August 1989 and September 
2013, from Ogaki Municipal Hospital, Japan. Median follow-up was 
11.1 years (95% CI 10.3, 11.8), and the number of recorded obser-
vations per patient ranged from 6 to 791 (median, 67). None of the 
patients received direct-acting antiviral agents.
2.4  |  Statistical methods
All statistical analyses were carried out using Stata/SE 14.2. Median 
and interquartile range (IQR) were presented for the continuous 
variables and percentages for the categorical variables. SVR and 
non-SVR groups were analysed separately. Overall survival time (ex-
pressed in months) was calculated from date of start of treatment 
(ie, ‘baseline’) to date of death. Patients who were still alive at last 
follow-up time were censored. Time to clinically significant deterio-
ration (new episode of encephalopathy, ascites, episode of variceal 
haemorrhage or admission with sepsis or death) was calculated from 
start of treatment to the date of first new decompensation event 
(ascites, paracentesis, encephalopathy and variceal bleed). Patients 
who did not decompensate were censored. Baseline variables avail-
able in all three cohorts were age, gender, HCV genotype, albumin 
(g/L), bilirubin (µmol/L), platelet count, date of start of treatment 
and date of death/last follow-up. Date of first decompensation was 
available for the DAA patients only.
ALBI score was the primary measure used in this study, defined 
as:
This produces a continuous score, which can either be used as is, 
or can be divided into ALBI grades according to the published cut-
offs 8: Grade 1, best liver function (≤−2.6), grade 2 (−2.6 to −1.39) and 
grade 3 (worst liver function(>−1.39).
Longitudinal data showing change in ALBI score over time were 
available for all three cohorts. Amongst the DAA patients, albumin 
and bilirubin were measured at baseline, then at pre-specified time 
intervals (typically, after 2, 4, 8 and 12 weeks during treatment) and 
a number of times after treatment. In the Japanese IFN cohort, sam-
ples were recorded at irregular intervals. Longitudinal data for FIB-4 
and platelet count were available for the Japanese IFN and DAA co-
horts, but not for the UK DAA patients.
2.5  |  Kaplan-Meier survival analysis
Overall survival according to (a) each of the three cohorts, (b) SVR 
status and (c) baseline ALBI grade was assessed via Kaplan-Meier 
analysis. Time to decompensation according to ALBI grade was also 
generated for the DAA patients. Using Cox regression, hazard ratios 
and p-values were estimated for comparing between survival groups.
2.6  |  Changes in the ALBI score
For a subset of patients with longitudinal data, to visualize changes 
in the ALBI score over time post-treatment, aggregate curves were 
generated for SVR and non-SVR patients separately via two methods:
(i) Fractional polynomial regression: A curve based on fractional 
polynomial (FP) regression was fitted to each patient so that values 
at fixed time points could be interpolated and an aggregate curve 
thereby generated. ALBI score was used as dependent variable and 
time post-treatment commencement as the explanatory variable. 
Specifically, in fitting these functions, we considered both first- and 
second-degree functions (FP1 and FP2, respectively). A selection 
procedure was then used to select the ‘best’ FP function model (ie 
the one with the lowest deviance). Using the selected FP function 
for each patient, we were able to generate predicted values for each 
patient at various time points. From these predictions, we calculated 
the median at regular six-monthly time points. 95% confidence inter-
vals were generated by the bootstrap method.
(ii) Linear regressions: A curve based on linear regression mod-
els was fitted for each patient, using square and cubic terms where 
appropriate. ALBI score was used as dependent variables and time 
post-treatment as explanatory variable. For each patient, model-pre-
dicted values at various time points were generated. Median values 
of all patients at each of these time points were then calculated. 95% 
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The fractional polynomial method requires a minimum of 4 observa-
tions in order to construct a curve for a patient. Due to long follow-up, 
this was possible to undertake in the Japanese IFN patients. However, 
in the DAA cohorts, follow-up was shorter (about 24 months) and the 
average number of observations per patient was less. In this case, linear 
regression was used to construct the aggregate curves.
3  |  RESULTS
There was a significant difference in survival between the UK group with 
decompensated disease and the Japanese with compensated disease 
(Figure 1). Those who achieved SVR survived longer in the UK cohort 
(P < .0001) but the number of events in the Japanese data set was too 
small for meaningful statistical analysis. (Figure 2). Of the 602 patients in 
the UK cohort, 467 (77.6%) achieved SVR at 12 weeks. Eighty-four died 
during follow-up and 119 were determined to have had a clinically sig-
nificant deterioration event during a total follow-up time of 1033 person 
years. In the Japanese cohort, 99% achieved SVR although for a small 
percentage (1.9%), this required a second course of DAA therapy.
3.1  |  Overall survival and 
clinically significant deterioration according to 
ALBI grade
There was some survival discrimination according to baseline 
ALBI grade in the UK decompensated cohort (Figure 3). In the 
same cohort, baseline ALBI grade also showed three distinct 
groups with different time to first decompensation (Figure 4). 
Equivalent analysis in the Japanese DAA patients was not pos-
sible as the number of patients with the relevant outcomes was 
very low.
3.2  |  Changes in ALBI score over time—impact of 
treatment on the ALBI score
For a subset of patients, longitudinal data were available for 571 
Japanese patients (including 9 achieving SVR) and 469 UK patients 
(including 77 achieving SVR). These were used to examine changes 
in ALBI score over time.
F I G U R E  1  Overall survival according to cohort. Kaplan-Meier plots. Note that the vertical axis starts as 0.85 to make the difference 
between the cohorts easier to visualize and the time (horizontal axis) is limited to 25 mo so that the cohorts are presented over a comparable 
time period
Overall survival by cohort 
Dataset 
% survival at 0.5 
year (95% CI) 
% survival at 1 
year (95% CI) 
% survival at 2 




Japan DAA 99.9 (98.9, 99.98) 99.7 (98.8, 99.9) 98.6 (96.8, 99.4) 1 reference 
UK DAA 94.2 (92.0, 95.8) 90.2 (87.5, 92.3) 85.7 (82.6, 88.3) 14.3 (6.2, 32.7) <0.0001 
Japan IFN 100 100 99.7 (99.2, 99.9) 0.2 (0.1, 1.0) 0.045 
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3.3  |  UK DAA cohort
The mean ALBI score at baseline was −1.76 (CI −1.82, −1.72), while 
the mean ALBI score for the last ALBI was a significantly better 
(P < .01) at −2.04 (CI −2.09, −1.99). The median interval between 
these first and last measurements was 8.9 months (IQR 5.7, 15.2), 
meaning that for a large majority of patients, the last ALBI measure-
ment was taken well after treatment was completed. Patients who 
achieved an SVR within 12 weeks of the end of treatment improved 
significantly more (change of −0.31) than those who did not (change 
of −0.14), P = .0031 (Figure 5A,B).
3.4  |  Japanese Interferon cohort of non-
SVR patients
In the interferon-based group, survival at 20 years was 89.00% 
(95% CI 84.21, 92.41) in the SVR group compared to 66.13% (95% 
CI 59.25, 72.13) in the non-SVR group. Among the 134 patients in 
the Japanese interferon-based cohort who died, the major cause 
of death was HCC (45.5%) and, of these, the great majority (90.2%) 
occurred among the group who did not achieve SVR. Overall only 
5.22% of those who died (or 0.63% overall) were recorded as dying 
from liver failure, the great majority of these (85.7%) also being in 
the non-SVR group.
Among the SVR cohort, the ALBI score improved slightly over 
the first 4 years and then remained largely stable for up to 24 years. 
By contrast, in the non-SVR group, after a small initial improvement 
there was a steady deterioration in liver function (Figure 5).
It is of particular interest to note that the early changes in ALBI, 
over the 2 years following initiation of DAA treatment, are very 
closely reflected in the first few years of the interferon-based treat-
ment cohort in that in both SVR and non-SVR, there is an improve-
ment in liver function. However, with insight into the long-term 
outcome it is apparent that among the SVR patients liver function 
stabilized whereas there was a steady deterioration in the non-SVR 
group.
4  |  DISCUSSION
Our study design permits us to assess the impact of a broad range of 
antiviral treatments on liver function, most pertinently the recently 
developed direct-acting antiviral agents in both the decompensated 
and compensated cirrhosis settings. Thus, in Japan the DAAs have 
been restricted to patients with compensated disease whereas in 
F I G U R E  2  Overall survival in UK patients receiving direct-acting antiviral agents (DAAs) according to sustained virological response (SVR) 
status. Kaplan-Meier plots
Overall survival by SVR 
Dataset SVR status 
% survival at 0.5 
year (95% CI) 
% survival at 1 
year (95% CI) 
% survival at 2 





Non-SVR 76.3 (68.2, 82.6) 70.4 (61.9, 77.3) 61.3 (52.1, 69.3) 1 reference 
SVR 99.4 (98.0, 99.8) 95.9 (93.7, 97.4) 92.5 (89.7, 94.6) 0.2 (0.1, 0.2) <0.0001 
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the UK, they were initially confined to patients with decompensated 
disease on the grounds that these were at the most imminent risk of 
death from liver failure. However, in both instances the follow-up is, 
of necessity, short, and therefore, our long-term data on the impact 
of interferon-based therapy on survival and liver function allow us to 
reasonably extrapolate DAA-related changes in liver function over 
the longer term.
Here, we document that liver function improves in patients re-
ceiving DAAs, particularly in those who achieve SVR, and most strik-
ingly in those who have decompensated disease. The changes in the 
DAA cohort in a 3-year period are very similar in character to those 
seen in the interferon-treated groups over the first 3 years suggest-
ing that the DAA cohort is likely to experience similar beneficial 
changes over the longer term as was seen in the interferon-treated 
group.
Our method of irregular time series analysis, together with the 
extensive serial data and use of the ALBI score (rather than the 
Child-Pugh score), allows us to visualize and quantify these changes 
over time. It is apparent, in all datasets, that even in those who do 
not achieve SVR, there is modest improvement in liver function over 
the first 3 years after initiation of therapy. We assume that even in 
the non-SVR group, there is transient improvement in liver function 
associated with a fall in viral load on treatment (indeed we know 
this to be the case because they include some patients who relapsed 
after initial response) that persists for a short time following treat-
ment, but recurs with the post-treatment rise in viral load and subse-
quent recurrence of liver injury.
It is also striking that, associated with the improvement in liver 
function, there is, in the UK cohort with decompensated disease, 
clear evidence of survival benefit in those achieving SVR (compared 
to those not achieving SVR) even over the short period of follow-up. 
Again, extrapolating from the Interferon-treated group there is clear 
evidence of long-term survival benefit with the achievement of SVR 
although it is important to note that this benefit is consequent upon 
the decreased incidence of HCC rather than any improvement in mor-
tality from liver failure, the incidence of which was, in fact, very low.
The marked reduction in deaths from HCC, consequent on 
achieving SVR, has also been widely reported but it has been noted 
that, although the risk of HCC is decreased in the SVR group, it is not 
abrogated completely. Indeed, in the largest study to date of HCC 
arising after SVR it is striking that the HCCs occurred very shortly 
after SVR with a median development time of only 1.66 years.14
In summary, we have demonstrated that DAA treatment results 
in improved liver function and survival particularly in patients who 
achieve SVR, compared to those who do not. Amongst patients 
with decompensated liver disease, liver function clearly impacts on 
F I G U R E  3  Overall survival in the entire UK cohort according to baseline albumin-bilirubin (ALBI) grade. Kaplan-Meier plots




% survival at 0.5 
year (95% CI) 
% survival at 1 
year (95% CI) 
% survival at 2 





1 100 94.2 (83.2, 98.1) 90.1 (77.9, 95.8) 1 reference 
2 94.8 (92.0, 96.6) 92.1 (88.9, 94.4) 88.3 (84.6, 91.2) 1.2 (0.5, 3.1) 0.641 
3 91.2 (85.8, 94.6) 84.7 (78.4, 89.3) 78.6 (71.4, 84.2) 2.3 (0.9, 5.9) 0.079 
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survival and the likelihood of further adverse liver-related events. 
The changes in liver function and survival with DAAs mirror, in the 
short term over which they have been observed, analogous results in 
a population receiving interferon-based therapy. In the latter cohort, 
such changes were, on long follow-up, associated with improved 
liver function and survival. It is likely that the DAA-mediated im-
provement of liver function in patients who achieve SVR will trans-
late into survival benefit.
F I G U R E  4  Time to decompensation (clinically significant deterioration) according to baseline albumin-bilirubin (ALBI) grade in the entire 
UK cohort. Kaplan-Meier plots




% survival at 0.5 
year (95% CI) 
 
% survival at 2 





1 5.8 (1.9, 16.8) 7.8 (3.0, 19.4) 9.8 (4.2, 21.9) 1 reference 
2 13.6 (10.5, 17.5) 16.6 (13.2, 20.8) 17.2 (13.7, 21.4) 1.9 (0.7, 4.6) 0.183 
3 26.8 (20.7, 34.2) 29.9 (23.6, 37.5) 29.9 (23.6, 37.5) 3.6 (1.4, 9.1) 0.006 
F I G U R E  5  A and B, Changes in albumin-bilirubin (ALBI) score over time in the (A) UK DAA and the (B) Japanese interferon cohorts. Note 
the similarity in the changes between the two cohorts over the first 3 y
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